FluGen has added $5.5 million to its coffers to prepare for the next round of studies on RedeeFlu, the nasal spray vaccine the Madison company has developed to protect against influenza.

CEO Paul Radspinner says the company is wrapping up its analysis of data from a study of nearly 100 healthy adults, designed to determine the safety of RedeeFlu and the appropriate dose. Results are not expected to be available until early 2018 but Radspinner said they were good enough to give the company confidence to move forward with a series of three studies next year.

One test will be with children and adolescents, ages 9-18; another will involve adults ages 50 and up; and the third will be a challenge study in which half the subjects receive the vaccine and half get the placebo and all are “challenged” with the influenza virus. A total of 250 to 300 participants will be involved in the three studies. Read the full story here.
Read the Xconomy story here: Fresh Off New Funding Round, FluGen Plans 3 Clinical Trials for 2018